大行評級 | 摩根士丹利給予榮昌生物超配評級,預計公司豐富的產品線將驅動股價
彭博新聞社報道,摩根士丹利稱,預計榮昌生物將會有強勁的股價表現,受其使用專用平臺開發的豐富產品線驅動。首次覆蓋給予公司超配評級,目標價83港元。
分析師Sean Wu等在報告中指出,榮昌生物開發的用於癌症、自身免疫性疾病以及眼疾方面的生物藥物,目前仍有大量未滿足需求的患者。
生物藥物可能會在這三個領域中,繼續從化學藥物中獲得市場份額。
公司擁有超過10種的候選藥物,全部基於內部研發。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.